<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459626</url>
  </required_header>
  <id_info>
    <org_study_id>1.02</org_study_id>
    <nct_id>NCT02459626</nct_id>
  </id_info>
  <brief_title>Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>STIFFMAP</acronym>
  <official_title>Comparison of Non-invasive Assessment of Cardiac Fibrosis by MRI Derived T1-Mapping and Ventricular Intrinsic Diastolic Function by Pressure-volume-analysis in Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      StiffMAP-HFpEF trial is an investigator initiated, observational, single-center study that
      will evaluate whether fibrosis quantification by cardiac MRI correlates with left and right
      ventricular stiffness derived from pressure-volume analysis, aiming to clarify if cardiac MRI
      is a valid, non-invasive method to assess diastolic function in patients with Heart Failure
      with preserved ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with preserved ejection fraction (HFpEF) and diastolic dysfunction is a growing
      medical challenge. To date almost every second patient with heart failure has a preserved
      ejection fraction and recent data show that outcomes in these patients are as bad as in those
      with reduced ejection fraction. In clinical routine the diagnosis of HFpEF is complicated by
      indirect assessment of diastolic function. Mechanistically the diastolic dysfunction is among
      others believed to be caused by the development of diffuse myocardial fibrosis with an
      increase of extracellular matrix.

      Direct assessment of the intrinsic diastolic function and stiffness of the ventricle can be
      obtained by pressure-volume-curve tracings through a conductance catheter. Although this
      offers the benefit of assessing load-dependent and load-independent parameters of diastolic
      function as well as information on contractility and ventricular-arterial coupling, the use
      of this technique is limited by its invasiveness in daily care.

      Newer MRI techniques have made it possible to quantify not only local fibrosis but also
      diffuse fibrosis (i.e. T1-Mapping) and determine extracellular volumes.

      Moreover, the role of right ventricular function is in HFpEF is not well defined.

      Aim of the current study is therefore to evaluate the role of MRI in assessing cardiac
      fibrosis in the context of impaired LV diastolic function in HFpEF patients, as well as to
      evaluate the role of systolic and diastolic right ventricular functional impairment in this
      patient cohort.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of extracellular volume (MRI) and myocardial stiffness (p-v-loops)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LV stiffness constant (ß) between groups</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time constant of LV-relaxation (Ƭ) between groups</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endiastolic pressure volume relation (EDPVR) under excercise between groups</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Endsystolic Elastance Slope</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Endsystolic Stiffness Constant</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>HFpEF and servere diastolic dysfuntion</arm_group_label>
    <description>Left ventricular ejection fraction (LV-EF) &gt; 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=&gt;2, Diagnostic P-V-loops and MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFpEF no servere diastolic dysfuntion</arm_group_label>
    <description>LV-EF &gt; 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=&gt;2, Diagnostic P-V-loops and MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No HF or diastolic dysfunction</arm_group_label>
    <description>LV-EF &gt; 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic P-V-loops and MRI</intervention_name>
    <description>Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function</description>
    <arm_group_label>HFpEF and servere diastolic dysfuntion</arm_group_label>
    <arm_group_label>HFpEF no servere diastolic dysfuntion</arm_group_label>
    <arm_group_label>No HF or diastolic dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Recruitment of consequtive patients from our general cardiology clinic that present with
        signs of heart failure or suspected CAD with indication for invasive assessment and
        fullfill eligibility criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LV-EF &gt; 50%

          -  Indication for invasive cardiac catheterization

        Exclusion Criteria:

          -  know CAD or CAD in Angiography (stenoses &gt; 50%)

          -  acute coronary syndromes

          -  Cerebral ischemia within the last year

          -  contraindications for MRI

          -  more than mild valvular disease

          -  Constrictive pericarditis, restrictive Cardiomyopathy, pericardial effusion

          -  pregnancy

          -  enrolment in other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Lurz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center of the University Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9.</citation>
    <PMID>16855265</PMID>
  </reference>
  <reference>
    <citation>Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9.</citation>
    <PMID>16855266</PMID>
  </reference>
  <reference>
    <citation>Burkhoff D, van der Velde E, Kass D, Baan J, Maughan WL, Sagawa K. Accuracy of volume measurement by conductance catheter in isolated, ejecting canine hearts. Circulation. 1985 Aug;72(2):440-7.</citation>
    <PMID>4006150</PMID>
  </reference>
  <reference>
    <citation>Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschöpe C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008 Apr 22;117(16):2051-60. doi: 10.1161/CIRCULATIONAHA.107.716886. Epub 2008 Apr 14.</citation>
    <PMID>18413502</PMID>
  </reference>
  <reference>
    <citation>Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012 Dec;265(3):724-32. doi: 10.1148/radiol.12112721. Epub 2012 Oct 22.</citation>
    <PMID>23091172</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Philipp Lurz</investigator_full_name>
    <investigator_title>PD Dr. Philipp Lurz, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

